Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies.
Copyright 2023 – Finance News Network
30 Jan 2024 - Linius Technologies (ASX:LNU) achieves historic milestone, powering IMG and Peach Belt Conference, reshaping sports and entertainment content access worldwide.
07 Jun 2023 - Novonix Limited (ASX:NVX) CEO Dr Chris Burns discusses the company's joint research and development agreement with South Korean battery cell manufacturer LG Energy Solution.
19 Nov 2019 - Redcape Hotel Group Limited (ASX:RDC) CEO, Dan Brady discusses FY19 results, company strategy and creating pub venues that become the hub of local communities.
11 Sep 2019 - BluGlass Limited (ASX:BLG) Managing Director Giles Bourne discusses partnering with LED lighting developer Bridgelux, enabling smaller and cheaper LEDs, and what the future holds with BLG’s new facility.
30 Mar 2020 - XTEK Limited (ASX:XTE) Managing Director Philippe Odouard talks 1H20 results, the company's front-line products for the Australian Defence Force and police forces, US strategy and outlook.
01 Oct 2024 - Hazer Group Limited (ASX:HZR) CEO Glenn Corrie provides an update on the company, discussing IP protection and moving into commercialisation.
01 Sep 2021 - Novatti Group Limited (ASX:NOV) CEO Peter Cook, discusses highlights from FY21, including growth in partners and transactions as the company's technology finds greater adoption and new markets.
03 Jun 2020 - Cyclopharm (ASX:CYC) Managing Director and CEO James McBrayer provides an update on US FDA progress with Technegas, approval in Russia and potential use of Technegas in the diagnosis and management of COVID-19.
30 Sep 2020 - Nuheara Limited (ASX:NUH) Managing Director & CEO Justin Miller provides an update on the company's range of innovative audio wearables, changes in its marketing and distribution as a result of COVID19, financial position and outlook.